PDF(Pubmed)
Abstract：
UNASSIGNED: There is currently no published evidence demonstrating the effectiveness and safety of subanaesthetic doses of ketamine, when administered intravenously as an adjunct treatment for depressive symptoms, in a real world setting in South Africa.
UNASSIGNED: This retrospective chart review reports the clinical response (change in Patient Health Questionnaire - 7 score) to an initial infusion series of ketamine added to usual treatment, and the pattern of its subsequent maintenance use, for depressive symptoms.
UNASSIGNED: A private ketamine clinic in Hilton, KwaZulu-Natal.
UNASSIGNED: The medical records of all patients who attended a private ketamine clinic between August 2019 and 31 May 2021 were retrospectively analysed. Depression symptoms were evaluated using the Patient Health Questionaire-9 (PHQ-9) administered immediately before and 24 h after each treatment. Response was defined as a score decrease of more than 50%.
UNASSIGNED: Among the 154 patients who received ketamine infusions for depression, 67 completed a six infusion initial series, with a response rate of 60.6% and remission rate of 32.4%. Of the 154, 50% no longer experienced any suicidal ideation after treatment and adverse events were uncommon, with 6.2% of infusions requiring intervention for adverse events, mostly nausea. In addition, 48.5% of those who completed the initial series continued to receive maintenance infusions, with no evidence of escalating use or abuse.
UNASSIGNED: Incorporating intravenous ketamine into the existing treatment regimens at a private clinic was associated with reduced acuteness of depression severity and suicidal ideation. This approach appeared safe and tolerable, showing no signs of abuse or dependence.
UNASSIGNED: This is the first known naturalistic study reporting on ketamine use for depressive symptoms in South Africa.
UNASSIGNED: This retrospective chart review reports the clinical response (change in Patient Health Questionnaire - 7 score) to an initial infusion series of ketamine added to usual treatment, and the pattern of its subsequent maintenance use, for depressive symptoms.
UNASSIGNED: A private ketamine clinic in Hilton, KwaZulu-Natal.
UNASSIGNED: The medical records of all patients who attended a private ketamine clinic between August 2019 and 31 May 2021 were retrospectively analysed. Depression symptoms were evaluated using the Patient Health Questionaire-9 (PHQ-9) administered immediately before and 24 h after each treatment. Response was defined as a score decrease of more than 50%.
UNASSIGNED: Among the 154 patients who received ketamine infusions for depression, 67 completed a six infusion initial series, with a response rate of 60.6% and remission rate of 32.4%. Of the 154, 50% no longer experienced any suicidal ideation after treatment and adverse events were uncommon, with 6.2% of infusions requiring intervention for adverse events, mostly nausea. In addition, 48.5% of those who completed the initial series continued to receive maintenance infusions, with no evidence of escalating use or abuse.
UNASSIGNED: Incorporating intravenous ketamine into the existing treatment regimens at a private clinic was associated with reduced acuteness of depression severity and suicidal ideation. This approach appeared safe and tolerable, showing no signs of abuse or dependence.
UNASSIGNED: This is the first known naturalistic study reporting on ketamine use for depressive symptoms in South Africa.
摘要：
■目前没有公开的证据证明氯胺酮亚麻醉剂量的有效性和安全性，当静脉注射作为抑郁症状的辅助治疗时，在南非的现实世界中。
本回顾性图表回顾报告了在常规治疗中添加氯胺酮的初始输注系列的临床反应（患者健康问卷的变化-7分），以及其后续维护使用的模式，抑郁症状。
■希尔顿的一家私人氯胺酮诊所，夸祖鲁-纳塔尔省.
对2019年8月至2021年5月31日期间在私人氯胺酮诊所就诊的所有患者的医疗记录进行回顾性分析。在每次治疗之前和之后24小时使用患者健康问卷-9（PHQ-9）评估抑郁症状。反应定义为评分下降超过50%。
■在154名接受氯胺酮输注的抑郁症患者中，67完成了六次输注初始系列，有效率为60.6%，缓解率为32.4%。在154人中，50%在治疗后不再有任何自杀意念，不良事件并不常见。6.2%的输液需要对不良事件进行干预，主要是恶心。此外,完成初始系列的人中有48.5％继续接受维持输液，没有证据表明使用或滥用不断升级。
■在私人诊所将静脉注射氯胺酮纳入现有治疗方案与降低抑郁严重程度和自杀意念的严重性相关。这种方法看起来是安全和可以容忍的，没有滥用或依赖的迹象。
■这是南非第一个已知的关于氯胺酮用于抑郁症状的自然研究报告。
本回顾性图表回顾报告了在常规治疗中添加氯胺酮的初始输注系列的临床反应（患者健康问卷的变化-7分），以及其后续维护使用的模式，抑郁症状。
■希尔顿的一家私人氯胺酮诊所，夸祖鲁-纳塔尔省.
对2019年8月至2021年5月31日期间在私人氯胺酮诊所就诊的所有患者的医疗记录进行回顾性分析。在每次治疗之前和之后24小时使用患者健康问卷-9（PHQ-9）评估抑郁症状。反应定义为评分下降超过50%。
■在154名接受氯胺酮输注的抑郁症患者中，67完成了六次输注初始系列，有效率为60.6%，缓解率为32.4%。在154人中，50%在治疗后不再有任何自杀意念，不良事件并不常见。6.2%的输液需要对不良事件进行干预，主要是恶心。此外,完成初始系列的人中有48.5％继续接受维持输液，没有证据表明使用或滥用不断升级。
■在私人诊所将静脉注射氯胺酮纳入现有治疗方案与降低抑郁严重程度和自杀意念的严重性相关。这种方法看起来是安全和可以容忍的，没有滥用或依赖的迹象。
■这是南非第一个已知的关于氯胺酮用于抑郁症状的自然研究报告。
